Birchview Capital’s Coherus Oncology CHRS Stock Holding History

Birchview Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-82,000	Closed	-$113K	–	69
2024 Q4	$113K	Sell	82,000 -290,000	-78%	-$325K	0.09%	62
2024 Q3	$387K	Buy	372,000 +102,000	+38%	+$140K	0.34%	36
2024 Q2	$467K	Hold	270,000	–	–	0.43%	33
2024 Q1	$645K	Buy	270,000 +160,000	+145%	+$394K	0.53%	31
2023 Q4	$366K	Buy	+110,000	New	+$295K	0.29%	40
2017 Q1	–	Sell	-7,500	Closed	-$211K	–	43
2016 Q4	$211K	Hold	7,500	–	–	0.13%	35
2016 Q3	$201K	Hold	7,500	–	–	0.12%	37
2016 Q2	$127K	Hold	7,500	–	–	0.09%	43
2016 Q1	$159K	Hold	7,500	–	–	0.11%	39
2015 Q4	$172K	Hold	7,500	–	–	0.1%	40
2015 Q3	$150K	Hold	7,500	–	–	0.1%	40
2015 Q2	$217K	Hold	7,500	–	–	0.11%	38
2015 Q1	$229K	Buy	+7,500	New	+$194K	0.12%	37

Other funds holding CHRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Birchview Capital's CHRS Position: Q1 2025 in Review

Birchview Capital sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 82,000 shares — an estimated $113K sold.

Birchview Capital first reported a position in CHRS in Q1 2015 and held it in 13 quarters. The position peaked at $645K in Q1 2024. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

Birchview Capital reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
Birchview Capital sold 82,000 Coherus Oncology shares in Q1 2025, an estimated $113K.
Birchview Capital first reported a position in Coherus Oncology in Q1 2015 and held it in 13 quarters.
Birchview Capital's Coherus Oncology position peaked at $645K in Q1 2024.
117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.